Zoster Vaccine Recombinant, Adjuvanted (Shingrix)
Zoster Vaccine Recombinant, Adjuvanted is an FDA-licensed reference biologic from GlaxoSmithKline Biologicals. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2017
Reference approved
Reference product
Shingrix Zoster Vaccine Recombinant, Adjuvanted
GlaxoSmithKline Biologicals
- Approved
- Oct 20, 2017
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for Zoster Vaccine Recombinant, Adjuvanted, in chronological order.
Reference approval
Approval date of the reference Zoster Vaccine Recombinant, Adjuvanted product.
8 yr 9 mo ago
Frequently asked questions
Are there biosimilars approved for Zoster Vaccine Recombinant, Adjuvanted (Shingrix)?
No 351(k) biosimilars or interchangeable biosimilars referencing Zoster Vaccine Recombinant, Adjuvanted are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.